SCHEMBL6042973

SCHEMBL6042973

CN(C)C(=O)CC1CCCCCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
EPHX1 P07099 2/20 0.45
HPGD P15428 2/20 0.45
ALOX5 P09917 2/20 0.41
EPHX2 P34913 2/20 0.38
ALDH1A1 P00352 1/20 0.38
DPP4 P27487 1/20 0.38
ADH1C P00326 2/20 0.37
ADH1A P07327 2/20 0.37
MEN1 O00255 1/20 0.37
ALPL P05186 1/20 0.37
POLB P06746 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
P2RX7 Q99572 1/20 0.36
ADH1B P00325 1/20 0.35
ADH4 P08319 1/20 0.35
ADH7 P40394 1/20 0.35
CTSK P43235 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8684586 1.00 KMT2A (0.45) KMT2AEPHX1HPGDALOX5EPHX2
SCHEMBL16055768 0.98 KMT2A (0.42) KMT2AEPHX1HPGDALOX5EPHX2
SCHEMBL16399328 0.88
SCHEMBL25044601 0.82 DPP4 (0.34) KMT2AEPHX1HPGDALOX5ALDH1A1
SCHEMBL24337119 0.80 DPP4 (0.34) EPHX1ALOX5ALDH1A1DPP4NPC1
SCHEMBL9846849 0.79 EPHX1 (0.40) KMT2AEPHX1HPGDALOX5EPHX2
SCHEMBL7387651 0.79 EPHX1 (0.44) KMT2AEPHX1HPGDALOX5ALDH1A1
SCHEMBL9732660 0.78 GABRA5 (0.44) EPHX1DPP4
SCHEMBL15340722 0.78 DPP4 (0.33) ALOX5ALDH1A1DPP4
SCHEMBL24127567 0.78 HPGD (0.48) KMT2AHPGDALDH1A1DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides ELAN PHARMACEUTICALS, INC. 2006-04-27 US disclosed
WO-2003103652-A1 METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES ELAN PHARMACEUTICALS, INC. (US) 2003-12-18 WO disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides APP, BACE1, BACE2 KMT2A 2309/4885EPHX1 447/4885HPGD 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.